
Cybin Inc. (NEO: CYBN) (NYSE:CYBN), a biopharma company focused on progressing “psychedelics to therapeutics” through proprietary drug discovery platforms announced its financial and business results ended March 31, 2022.
The monetary assessment (in Canadian dollars) showed: